Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT06733987Recruiting
Pembrolizumab and immune aging in relapsed Hodgkin lymphoma
This study looks at how a type of immune cell aging (called 'immunological senescence') might affect how well the drug pembrolizumab works in people whose Hodgkin lymphoma has come back or not responded to treatment.
BolognaAges 18 years+ - NCT06733610RecruitingPhase 1
CAR T-cell therapy for AIHA after 3 failed treatments
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07562022RecruitingPhase 3
SCTB35 Plus Lenalidomide for Resistant Follicular Lymphoma
This trial tests a new drug called SCTB35 combined with lenalidomide (a known cancer drug) in people whose follicular lymphoma (a type of blood cancer) has stopped responding to or come back after previous treatments. The combination may help shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–80 - NCT07559799Recruiting
Melflufen and Dexamethasone for Relapsed Multiple Myeloma
This study tracks how melflufen (a cancer-fighting drug) combined with dexamethasone works in patients with multiple myeloma that has returned or stopped responding to previous treatments. Researchers will monitor your health and quality of life over time to understand the treatment's real-world effectiveness.
Freiburg im BreisgauAges 18 years+ - NCT06732232RecruitingEarly Phase 1
CAR-T therapy for multiple myeloma that returned or didn't respond
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
ShanghaiAges 18–75 - NCT07566364RecruitingPhase 2
Mosunetuzumab for Chronic Lymphocytic Leukemia with Minimal Residual Disease
This study tests a new antibody drug called mosunetuzumab in patients with chronic lymphocytic leukemia (CLL) who have already tried other treatments and still have detectable leukemia cells in their bone marrow. The drug is designed to work in a way that might help your immune system fight the remaining cancer cells.
Houston, TexasAges 18 years+ - NCT07561424Recruiting
Comparing different dialysis membrane types for kidney patients
This study compares three types of dialysis filters to see which works best at removing waste from your blood and improving your health outcomes. If you receive regular hemodialysis at a clinic, this trial may help doctors understand which filter type is most effective for you.
ParisAges 18 years+ - NCT07561411Recruiting
Nerve blocks to reduce pain after breast removal surgery
This trial tests two types of nerve-blocking injections given during breast removal surgery to see which one better prevents long-term pain afterward. Both are given alongside general anesthesia and may help you recover with less chronic pain.
BeirutAges 18–80 - NCT07563582Recruiting
Iron Supplement for Children with Celiac Disease and Low Iron
This study tests whether a special iron supplement taken by mouth helps children who have celiac disease (a condition where the body can't digest gluten) and low iron levels or anemia (not enough healthy red blood cells). The iron supplement is designed to be easily absorbed by the body.
Genova, ItalyAges 8–18 - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT07566377RecruitingPhase 2
Cord Blood Transplant for Children and Young Adults With Blood Cancer
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
New York, New YorkAges Up to 26 years - NCT07562451Recruiting
How Music Therapy Affects Pain in Young People With Sickle Cell Disease
This study explores whether listening to music can help reduce chronic pain in young people with sickle cell disease. Researchers will use blood tests to understand how music affects your body's cells and your pain levels.
Atlanta, GeorgiaAges 8–18 - NCT07565220RecruitingPhase 1
Thiotepa-based stem cell transplant for blood cancers
This trial tests a new chemotherapy preparation (using thiotepa) before a stem cell transplant from a matched donor to treat blood cancers like leukemia and myelodysplastic syndrome. The goal is to improve survival while reducing severe side effects.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07564219Recruiting
Beta-Hydroxybutyrate to Boost CAR-T Cell Therapy in Multiple Myeloma
This trial tests whether a natural metabolite called beta-hydroxybutyrate can strengthen CAR-T cell therapy (a type of cancer-fighting cell treatment) in multiple myeloma patients. The goal is to help your immune cells work better against your cancer.
Hamburg, Free and Hanseatic City of HamburgAges 18 years+ - NCT07563179RecruitingPhase 2
Bugitinib with Venetoclax and Cytarabine for Relapsed AML
This trial tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) for patients with acute myeloid leukemia (AML) that has returned or didn't respond to prior treatments. The goal is to see if this combination can help patients achieve remission and improve survival.
Shenzhen, GuangdongAges 18–70 - NCT07561892RecruitingPhase 4
Chemotherapy with or without silibinin for newly diagnosed blood cancer
This trial tests whether adding silibinin (a plant-based supplement) to standard chemotherapy drugs (daunorubicin or idarubicin) helps treat newly diagnosed acute myeloid leukemia (AML), a serious blood cancer. The goal is to see if this combination is more effective and safer than chemotherapy alone.
Fuzhou, FujianAges 18–65 - NCT07564453RecruitingPhase 2
Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Suzhou, JiangsuAges 15–65 - NCT06735495RecruitingPhase 1/Phase 2
Two-target CAR T cells for relapsed B-cell blood cancers
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
Wuhan, HubeiAges 3–75 - NCT05839717Recruiting
Testing gene changes in PV or ET and blood clot risk
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
AngersAges 18 years+ - NCT06734637Recruiting
Peginterferon for essential thrombocythemia and polycythemia vera
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
Wuhan, HubeiAges 18 years+ - NCT06734520Recruiting
Super transplant for severe beta-thalassemia
This trial tests a special type of stem cell transplant (called a super transplant) for children with a severe form of beta-thalassemia. It may be an option if you cannot or choose not to have a standard stem cell transplant or gene therapy.
Guangzhou, GuangdongAges 7–10 - NCT06209606RecruitingEarly Phase 1
Blood test study for multiple myeloma progression
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
West Hollywood, CaliforniaAges 18 years+ - NCT06736860RecruitingPhase 4
Tranexamic acid for trauma bleeding with blood clot monitoring
This study tests whether a drug called tranexamic acid (TXA) can help control bleeding in trauma patients. It uses a special blood test (thromboelastography) to monitor how well your blood clots during treatment.
Guangzhou, GuangdongAges 18–80 - NCT06737250RecruitingPhase 2
Testing a new drug combo for relapsed brain lymphoma
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
BusanAges 19–80
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.